Since ETO administration in neuroblastoma cell lines affects the PHOX2B pathway through PGR activation [39], we investigated the cellular and molecular effects of ETO treatment within selected regions of the brain: the dorsomedial hypothalamus (DMH), locus coeruleus (LC), parafacial area (pF, including RTN and the facial nucleus, FN) and the DVC (including the nucleus of the solitary tract, NTS, area postrema, AP, and dorsal motor nucleus of the vagus, X). The gene discussed is PHOX2B; the disease is neuroblastoma.